FDA's top drug regulator, Tracy Beth H++eg, announced her focus on scrutinizing antidepressants and RSV shots for infants, signaling a shift in regulatory priorities that could impact drug safety assessments. Roche plans to cease manufacturing of its key antibiotic, Rocephin, by 2030 due to rising costs and generic competition, highlighting the financial challenges in maintaining production of essential antibiotics. For content creators, these developments underscore the importance of staying informed about regulatory changes and pharmaceutical industry dynamics to provide accurate and timely information.
Read the full article at STAT Pharma
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
